Article Type
Changed
Thu, 06/24/2021 - 12:10

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Publications
Topics
Sections

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: HCC June 2021
Gate On Date
Mon, 06/07/2021 - 10:30
Un-Gate On Date
Mon, 06/07/2021 - 10:30
Use ProPublica
CFC Schedule Remove Status
Mon, 06/07/2021 - 10:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article